By PG In NewsPosted September 28, 2021 Sentien Reports on Data from First Ph I/II Study of SBI-101 in Subjects with AKI in STEM CELLS Translational Medicine Read More
By PG In NewsPosted September 21, 2021 Sentien Biotechnologies Receives Award from Maryland Stem Cell Research Fund to Support Clinical Study of SBI-101 Read More
By PG In Press ReleasesPosted September 2, 2021 Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced [...] Read More
